local_hospital

Medizinische Versorgungszentren St. Josefs-Krankenhaus Potsdam GmbH

Address
Allee Nach Sanssouci 7, Brandenburger Vorstadt, 14471 Potsdam, Germany

Medizinische Versorgungszentren St. Josefs-Krankenhaus Potsdam GmbH

This medical center in Potsdam specializes in advanced neurological research, with a particular emphasis on autoimmune and inflammatory disorders affecting the nervous system. The facility conducts cutting-edge clinical trials investigating novel therapeutic approaches for debilitating neurological conditions.

  • Multiple sclerosis treatment development, focusing on relapsing forms of MS
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutic interventions
  • Immunomodulatory therapies targeting demyelinating diseases

The center's research portfolio demonstrates expertise in evaluating monoclonal antibody therapies and next-generation immunological treatments. Their clinical trials compare innovative biologics against established therapies, with comprehensive assessment of both efficacy and safety profiles in participants with relapsing neurological disorders. The facility's work contributes to understanding disease mechanisms and preventing relapse in chronic inflammatory conditions of the peripheral and central nervous systems.

Site Overview

assignment
4
connected trials
corporate_fare
3
sponsors
science
7
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
4
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
3
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
4
Outperforms 67% of sites
public
Therapeutic diversity
2areas
Outperforms 62% of sites
groups
Sponsor diversity
3sponsors
Outperforms 65% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Medizinische Versorgungszentren St. Josefs-Krankenhaus Potsdam GmbH

lock Showing 1 of 4 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety of Nipocalimab in Adults with Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double-Blind, Placebo-Controlled StudyJanssen Cilag InternationalPhase IIRecruitingOct 2022

IMP list

lock Showing 1 of 7 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Frexalimab2Unknown2024-11-192024-12-11

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.